Jeffrey V. Poulton sold $797k of ALNY
EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC.. 2,468 shares at an average of $323.08, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +22RoleCFO
- +22Trade size$797k at market
- 0Share of holdings soldSold 3.8% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-26-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | SOpen-market sale Common Stock | -114 | $319.03 | $36k | 64,159 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -109 | $320.01 | $35k | 64,050 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -230 | $320.81 | $74k | 63,820 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -309 | $321.82 | $99k | 63,511 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -374 | $323.01 | $121k | 63,137 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -818 | $323.84 | $265k | 62,319 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -291 | $324.88 | $95k | 62,028 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -223 | $325.67 | $73k | 61,805 | Mar 6, 2026 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.1M 3,492 shares | -13% | |
| 58Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $723k 2,206 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.